Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Comment by fairweather1on May 21, 2013 5:59pm
93 Views
Post# 21423116

RE: Another final Nav estimate

RE: Another final Nav estimate

good points from you and sanspeine.  I think your estimates are quite conservative (reasonable), and sanspeine's tax corrections add to the conversation, however I think it is a long shot to suggest that the Oakville leases will dovetail with another contract (not impossible; just less likely).

 

Of course, none of this takes into account the very good possibility of a wind contract (likely somewhere else) and the possibility of a positive gm settlement.  I have no idea of the likelihood of the gm settlement, but what a gift that would be.  Even if they only got 80% of what they are asking for, that would be $1 per share.

 

Back to what we know, IMO, if no litigation proceeds are received or new contracts obtained, we are looking at a minimum of $2.50.  Wind or litigation would be gravy.  So the only thing I would be nervous about is a major investment in something totally new that could tank.  

 

But management have squeezed a lot of profit out of complex, exacting, time sensitive work; it's not like someone's lemonade stand wasn't making money, so they are trying their hand at brain surgery.  Further, Chris Nutt owns a lot of shares.  He stands to lose like us if he squanders the cash.

 

I think the current $1.50 is crazy.

Bullboard Posts